Evenity (Romosozumab) Side Effects: Potentially Permanent Adverse Events Explained

What Is Romosozumab and Why Does the Side-Effect Profile Matter?

Romosozumab is a monoclonal antibody that blocks sclerostin, a protein secreted by osteocytes that normally suppresses bone formation. By inhibiting sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual action that no other approved osteoporosis drug achieves. The key FRAME trial (N=7,180) showed a 73% reduction in new vertebral fractures at 12 months versus placebo [1].

That efficacy comes with a risk profile unlike older osteoporosis agents. The cardiovascular signal, in particular, emerged late in clinical development and reshaped the drug's prescribing population entirely. Because the treatment course is exactly 12 monthly doses, patients and prescribers have a fixed, time-limited window to weigh benefit against potential permanent harm.

Mechanism and the Sclerostin-Cardiovascular Link

Sclerostin is not only expressed in bone. Vascular smooth muscle cells also produce it, and some research suggests sclerostin may protect against vascular calcification [2]. Blocking sclerostin systemically could therefore accelerate arterial calcification in susceptible individuals. This hypothesis, though still being studied, provides a biologically plausible explanation for the cardiovascular signal seen in ARCH.

Why "Permanent" Matters Here

Most drug side effects resolve after stopping treatment. The adverse events described in this article may not. A myocardial infarction can produce permanent left-ventricular dysfunction. Osteonecrosis of the jaw can require surgical debridement leaving lasting bone defects. Atypical femur fractures, once they occur, heal slowly and sometimes incompletely in older adults. Reviewing the permanence of these outcomes is therefore not a formality but a direct input into the shared decision-making process.

FDA Boxed Warning: Myocardial Infarction, Stroke, and Cardiovascular Death

The FDA placed a boxed warning on Evenity in 2019 specifically for myocardial infarction (MI), stroke, and cardiovascular death. This is the most serious warning category the FDA issues, and it came directly from the ARCH trial data [3].

The ARCH Trial Data in Detail

ARCH (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk, N=4,093) compared romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone for the full study duration. The primary fracture endpoints favored romosozumab decisively. Vertebral fractures were reduced by 48% and hip fractures by 38% compared with alendronate [4].

The cardiovascular finding, however, changed the drug's risk calculus. Serious cardiovascular events (MI, stroke, or cardiovascular death) occurred in 2.5% of romosozumab-treated patients versus 1.9% in the alendronate group, a 0.6 percentage-point absolute difference and a relative increase of approximately 31% [4]. The FDA's prescribing label states directly: "Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year." [3]

Cardiovascular Permanence: What the Data Show

An MI is not a transient event. Even a non-ST-elevation MI can produce myocardial scar tissue, reducing ejection fraction and raising the lifetime risk of heart failure. The cardiovascular deaths observed in ARCH were, by definition, non-reversible. This is what places the ARCH cardiovascular signal in the permanent-harm category.

A 2021 systematic review and meta-analysis published in the Journal of the American Heart Association analyzed pooled data from FRAME, ARCH, and two smaller trials. The pooled odds ratio for serious cardiovascular events with romosozumab was 1.56 (95% CI 1.02 to 2.38) compared with active or placebo controls [5]. That signal held even after excluding the ARCH alendronate-comparison arm.

Who Bears the Highest Cardiovascular Risk

Patients with pre-existing coronary artery disease, prior stroke, peripheral arterial disease, or uncontrolled hypertension are at greatest baseline cardiovascular risk. The Evenity prescribing label cautions that romosozumab should be used in such patients "only if the benefits clearly outweigh the risks." [3] In practice, this means a formal cardiology consultation may be appropriate before initiating therapy in anyone with established atherosclerotic cardiovascular disease.

Osteonecrosis of the Jaw (ONJ)

Osteonecrosis of the jaw is a condition in which jaw bone is exposed and fails to heal, typically after a dental procedure or minor trauma. Once established, it can progress to chronic pain, bone sequestrum, and the need for surgical debridement that permanently alters jaw anatomy.

Incidence in Osteoporosis vs. Oncology Dosing

ONJ is far more common at the high IV doses used in cancer care (e.g., zoledronic acid 4 mg every 3 to 4 weeks) than at osteoporosis doses. For antiresorptive agents used in osteoporosis, the American Association of Oral and Maxillofacial Surgeons (AAOMS) estimated ONJ incidence at 0 to 0.018% per 100 patient-years [6]. Romosozumab's mechanism is distinct from bisphosphonates and denosumab, but the Evenity prescribing label identifies ONJ as a potential risk based on post-marketing reports [3].

Clinical Presentation and Permanence

The defining feature is exposed bone in the oral cavity lasting more than 8 weeks without healing. Left untreated or in severe cases, ONJ can erode through the cortical plate, cause pathological fractures of the mandible, or create oro-antral fistulae. Surgical treatment removes necrotic bone, but the resected tissue does not regenerate fully.

The FDA label recommends a dental examination with appropriate preventive dentistry before initiating romosozumab in patients with risk factors: poor oral hygiene, invasive dental procedures, use of glucocorticoids, smoking, or diabetes [3].

Practical Pre-Treatment Protocol

Completing any invasive dental work (extractions, implant placements, periodontal surgery) before the first romosozumab injection reduces ONJ risk. After treatment begins, patients should maintain rigorous oral hygiene, receive routine cleanings only (not extractions), and notify their prescriber before any planned invasive procedure so the risk-benefit decision can be made with full information.

Atypical Femur Fractures (AFF)

Atypical femur fractures are low-energy or stress fractures of the femoral shaft that occur with minimal or no trauma. They are distinguishable from typical osteoporotic hip fractures both radiographically (transverse fracture line, medial cortical spike, periosteal or endosteal thickening) and clinically (often preceded by weeks of prodromal thigh pain) [7].

Link to Prior Antiresorptive Use

AFFs emerged as a recognized complication primarily with long-term bisphosphonate use, suppressing bone remodeling to the point where microcracks accumulate without repair. Romosozumab is a bone-forming agent with antiresorptive properties, and the prescribing label includes AFF as a potential risk, particularly in patients who transition to romosozumab after prolonged bisphosphonate therapy [3].

A 2020 case series published in Osteoporosis International documented AFF events in patients who received romosozumab following extended bisphosphonate courses, suggesting the prior antiresorptive exposure, not the romosozumab itself, may be the primary driver in most reported cases [7]. Still, prescribers are advised to evaluate any patient presenting with new thigh or groin pain during the 12-month course.

Permanence of AFF in Older Adults

AFFs heal slowly. Complete fractures require intramedullary nail fixation and often 3 to 6 months of restricted weight-bearing. Incomplete cortical stress reactions may heal conservatively, but functional impairment during healing, including muscle atrophy and cardiovascular deconditioning from immobility, can outlast the fracture itself. In patients over 70, the recovery trajectory after AFF is often measured in years.

Bilateral Risk

A distinctive feature of AFF is bilaterality. Roughly 28% of patients with one AFF develop a contralateral fracture within 2 years [8]. When a patient presents with unilateral AFF, imaging the contralateral femur is standard of care. This bilateral risk compounds the permanence concern considerably.

Hypocalcemia: Rapid-Onset and Potentially Severe

Romosozumab's anabolic bone effect sharply increases skeletal demand for calcium. If a patient begins therapy with pre-existing vitamin D deficiency or inadequate dietary calcium, the rapid transfer of calcium into new bone matrix can drop serum ionized calcium to dangerous levels.

Clinical Consequences of Severe Hypocalcemia

Mild hypocalcemia (serum calcium 8.0 to 8.5 mg/dL) causes perioral tingling and muscle cramps. Severe hypocalcemia (below 7.5 mg/dL) can cause seizures, laryngospasm, cardiac arrhythmias including QT prolongation, and tetany. These events, particularly cardiac arrhythmias, can cause permanent myocardial injury or hypoxic brain damage if not corrected rapidly.

The FDA label mandates pre-treatment correction of hypocalcemia and lists hypocalcemia as a contraindication for initiation [3]. The recommended supplementation standard is at least 1,000 mg of elemental calcium daily and 800 IU of vitamin D daily during the treatment course, with higher doses if baseline 25-OH-D is below 20 ng/mL.

Monitoring Schedule

Serum calcium and 25-OH-D should be checked before the first injection. For patients with chronic kidney disease, more frequent monitoring is warranted given their baseline tendency toward hypocalcemia and secondary hyperparathyroidism.

Injection-Site Reactions and Hypersensitivity

Injection-site reactions occurred in 5.1% of romosozumab-treated patients versus 2.9% in the placebo arm of FRAME [1]. Reactions include erythema, pain, and induration at the subcutaneous injection site (anterior thigh or abdomen). These are generally transient and resolve within 1 to 2 weeks.

Serious hypersensitivity reactions, including urticaria, erythema multiforme, dermatitis, and rare cases of angioedema, have been reported in post-marketing surveillance and are included in the prescribing label [3]. Angioedema involving the airway is potentially life-threatening and warrants immediate discontinuation and emergency intervention. In the rare instances where angioedema causes laryngeal edema and delayed airway compromise, the sequelae could be permanent.

Cardiovascular Risk in Context: Comparing Romosozumab to Alternatives

Putting the boxed warning in clinical perspective requires comparing it against the fracture burden romosozumab prevents.

FRAME vs. ARCH: Two Different Risk Populations

In FRAME, which compared romosozumab to placebo, no statistically significant difference in cardiovascular events was observed: 0.8% in the romosozumab group versus 0.5% in placebo (not statistically significant) [1]. The signal emerged predominantly in ARCH, where the comparator was alendronate. Some researchers have proposed that alendronate may itself carry a protective cardiovascular effect, making the ARCH comparator arm appear more favorable and inflating the apparent romosozumab risk [9].

Absolute Fracture Benefit vs. Absolute CV Risk

In the ARCH 12-month period, romosozumab prevented approximately 3.5 vertebral fractures per 100 patients treated compared with alendronate, while adding approximately 0.6 serious cardiovascular events per 100 patients treated [4]. For a patient with very high fracture risk and low cardiovascular risk (no prior MI, no prior stroke, no established CAD), the benefit-to-risk ratio is favorable. For a patient with recent MI or stroke, the FDA's contraindication is unambiguous.

The following decision framework can help structure the prescribing conversation:

HealthRX Romosozumab Risk-Stratification Framework

| Patient Profile | CV Risk | Fracture Risk | Recommended Approach | |---|---|---|---| | Prior MI or stroke <12 months | Contraindicated | Any | Do not initiate; use teriparatide or denosumab | | Established CAD, no recent event | High | Very high (FRAX hip >3%) | Cardiology co-management; consider alternatives first | | No CV disease history, T-score <-3.5 | Low-moderate | Very high | Romosozumab appropriate with dental clearance, Ca/D optimization | | Prior bisphosphonate >5 years | Low | High | Evaluate femur cortical thickness; AFF risk warrants imaging | | CKD stage 3b-4 | Moderate | High | Nephrology input; hypocalcemia monitoring every 2 weeks for first 3 months |

Post-Marketing Safety Data from FAERS

The FDA Adverse Event Reporting System (FAERS) database contains post-marketing reports for romosozumab dating from its April 2019 approval. As of publicly available quarterly extracts through mid-2024, the most frequently reported serious adverse events beyond the clinical trial data include:

• Cardiovascular events (MI, stroke, cardiac arrest) consistent with the boxed warning
• ONJ cases, predominantly in patients with prior bisphosphonate use or dental extractions during therapy
• AFF cases, again predominantly in patients with extensive prior antiresorptive history
• Hypocalcemia-related hospitalizations, most in patients with unrecognized vitamin D deficiency or CKD

FAERS data carry inherent limitations: reporting is voluntary, underreporting is common, and causality cannot be confirmed. Nonetheless, the pattern of serious event types in FAERS aligns closely with the label's identified risks, reinforcing rather than contradicting the clinical trial signal [10].

Drug Interactions and Factors That Amplify Permanent Risk

Several co-prescribing situations can intensify the risks described above.

Glucocorticoids

Glucocorticoid-induced osteoporosis is a common reason for advanced bone loss, and some of these patients may be candidates for romosozumab. However, chronic glucocorticoids increase ONJ risk, impair wound healing around dental procedures, and may worsen cardiovascular risk through hypertension and dyslipidemia. The combination warrants heightened monitoring.

Anticoagulants

Patients on warfarin, apixaban, or rivaroxaban who experience an MI during romosozumab therapy face both the primary cardiac event and heightened risk of hemorrhagic transformation if the MI involves thrombotic stroke. This interaction does not appear in the label as a formal drug-drug interaction, but it is clinically relevant to risk-benefit counseling.

Prior Denosumab

Sequential therapy from denosumab to romosozumab has been studied in small cohorts. Because both agents have antiresorptive components, the transition may prolong suppression of bone resorption, potentially elevating AFF risk cumulatively. The STRUCTURE trial (N=218) examined teriparatide after alendronate but not specifically denosumab-to-romosozumab sequencing at scale [11].

What Patients and Prescribers Should Do Before Starting Romosozumab

Pre-treatment evaluation is not optional with this drug. A systematic checklist reduces the risk of preventable permanent harm.

Mandatory Pre-Treatment Steps

1. Cardiovascular history review: confirm no MI or stroke within the prior 12 months; document established CVD status.
2. Dental examination: complete invasive procedures and allow 4 to 6 weeks of healing before starting.
3. Calcium and vitamin D: measure 25-OH-D; correct to at least 30 ng/mL; prescribe supplemental calcium 1,000 to 1,200 mg/day.
4. Renal function: calculate eGFR; for eGFR <30 mL/min/1.73m², the risk-benefit balance shifts significantly toward alternative agents.
5. Baseline femur X-ray: for patients with >5 years of prior bisphosphonate use, evaluate for cortical thickening or stress reaction before starting.

Monitoring During Treatment

Serum calcium re-check at week 4 after the first injection is a reasonable precaution for any patient with CKD, malabsorption, or baseline 25-OH-D below 20 ng/mL. Blood pressure monitoring at each monthly injection visit flags evolving hypertension. Patients should report any new chest pain, unilateral weakness, speech change, thigh pain, or jaw pain immediately.

Transition After the 12-Month Course

Romosozumab's bone-building effect is transient. Without sequential antiresorptive therapy after the 12-month course, bone mineral density returns toward baseline within 12 months [4]. The ARCH trial used alendronate as the follow-on agent. For patients with a contraindication to bisphosphonates (e.g., severe CKD, prior AFF on bisphosphonates), denosumab 60 mg every 6 months is a common alternative.

Failure to transition carries its own permanence risk: the fractures that romosozumab was preventing will recur as the anabolic effect wanes. The Endocrine Society's 2020 clinical practice guideline on osteoporosis states: "Sequential antiresorptive therapy is recommended after completing romosozumab treatment to maintain the gains in bone mineral density." [12]